Results for tag: "Short Acting Insulin"

Within the broader pharmaceutical category of Endocrine and Metabolic Disorders Drugs, Short-Acting Insulin represents a crucial therapeutic class for the management of diabetes. Insulin, a hormone produced by the pancreas, is essential for the regulation of blood glucose levels. Short-Acting Insulin, also known as regular or rapid-acting insulin, is designed to mimic the natural release of insulin in response to food intake, quickly reducing blood sugar levels post-mealtime. These insulins have a rapid onset of action, typically taking effect within minutes, and a relatively short duration, usually working for a few hours, thereby necessitating multiple daily injections to maintain optimal glycemic control. This class of insulin is particularly important for individuals with type 1 diabetes, who require an exogenous source of insulin due to autoimmune destruction of pancreatic beta cells, and for some individuals with type 2 diabetes who cannot be controlled with oral medications alone. The development and enhancement of Short-Acting Insulin formulations are continually evolving, with research focusing on improving onset time, peak action, and duration to more closely mimic physiological insulin release. Several key players operate in the Short-Acting Insulin market. Companies such as Novo Nordisk, Eli Lilly, Sanofi, and Biocon are prominent manufacturers of these medications, providing a range of products that cater to the diverse needs of patients with diabetes. Each company invests in research and development to improve their formulations, delivery systems, and to enhance patient compliance and Show Less Read more